Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2023

28-11-2022 | Positron Emission Tomography | Review Article

Current research topics in FAPI theranostics: a bibliometric analysis

Authors: Andor F. van den Hoven, Ruth G. M. Keijsers, Marnix G. E. H. Lam, Andor W. J. M. Glaudemans, Frederik A. Verburg, Wouter V. Vogel, Jules Lavalaye

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2023

Login to get access

Abstract

Purpose

The study aimed to provide a comprehensive bibliometric overview of the current scientific publications on fibroblast activation protein inhibitor (FAPI) positron emission tomography imaging and radionuclide therapy.

Methods

A PubMed search was performed to identify all MEDLINE-indexed publications on FAPI imaging and radionuclide therapy. The last update was performed on 31 May 2022. An online database of this literature was created, and hierarchical topic-related tags were subsequently assigned to all relevant studies. Frequency analysis was used to evaluate the distribution of the following characteristics: first author’s country of origin, journal of publication, study design, imaging techniques and radiopharmaceutical used, histopathological correlation, the type of cancer, and benign disease/uptake types evaluated.

Results

A total of 294 relevant publications on original studies were identified, consisting of 209 (71%) case reports/series and 85 cohort studies (29%). The majority of studies focused on imaging topics, predominantly comparing uptake on FAPI-PET/CT with 2-[18F]FDG-PET/CT, anatomical imaging, and/or histopathology results. 68% of studies focused on malignancies, with gastro-intestinal cancer, hepato-pancreato-biliary cancer, mixed cancers/metastases, lung cancer, sarcoma, head and neck cancer, and breast cancer being the most frequently reported. 42% of studies focused on benign disease categories, with cardiovascular, musculoskeletal, HPB, head and neck, and IgG4-related disease as most common categories. 16/294 (5%) studies focused on radionuclide therapy, with preliminary reports of acceptable toxicity profiles, tumour activity retention, and suggestion of disease control.

Conclusion

FAPI research is rapidly expanding from diagnostic studies in malignancies and benign diseases to the first reports of salvage radionuclide therapy. The research activity needs to shift now from low-level-of-evidence case reports and series to prospectively designed studies in homogenous patient groups to provide evidence on how and in which clinical situations FAPI theranostics can be of added value to clinical care. We have provided an overview of current research topics to build upon.
Appendix
Available only for authorised users
Literature
1.
Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J. Nucl. Med. [Internet]. 2021;62:160–7. Available from: None.
2.
3.
Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med [Internet]. 2019;60:386–92. Available from: None.CrossRefPubMedPubMedCentral
4.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J. Nucl. Med. [Internet]. 2019;60:801–5. Available from: None.
5.
Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann. Rheum. Dis. [Internet]. 2020;79:1485–91. Available from: None.
6.
7.
8.
9.
Frederik M. Glatting. Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions Frederik. J. Nucl. Med. [Internet]. 2022;None. Available from: None.
10.
Roth KS, Voltin C-A, van-Heek L, Wegen S, Schomaecker K, Fischer T, et al. Dual-tracer PET/CT protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for cancer imaging - a proof of concept. J Nucl Med [Internet]. 2022;63:1683–6. Available from: None.
11.
Dong A, Yang Q, Hua M, Cheng C, Zuo C. Lipid-poor renal angiomyolipoma mimicking renal cell carcinoma on 68Ga-FAPI-04 PET/CT. Clin. Nucl. Med. [Internet]. 2022;Publish Ah. Available from: None.
12.
Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:4396–414. Available from: None.
13.
Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2022;49:2844–68. Available from: None.
14.
Dorst DN, Rijpkema M, Buitinga M, Walgreen B, Helsen MMA, Brennan E, et al. Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy . Rheumatology [Internet]. 2021;None. Available from: None.
15.
Kuwert T, Schmidkonz C, Prante O, Schett G, Ramming A. FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases. J. Nucl. Med. [Internet]. 2022;None:jnumed.122.263922. Available from: None.
16.
17.
Röhrich M, Leitz D, Glatting FM, Wefers AK, Weinheimer O, Flechsig P, et al. Fibroblast activation protein-specific PET/CT imaging in dibrotic interstitial lung diseases and lung cancer: a translational exploratory study. J. Nucl. Med. [Internet]. 2022;63:127–33. Available from: None.
18.
Conen P, Pennetta F, Dendl K, Hertel F, Vogg A, Haberkorn U, et al. [68Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:3365–72. Available from: None.
19.
Yuan T, Wang X. 68Ga-FAPI PET/MRI in coronary heart disease. J. Nucl. Cardiol. [Internet]. 2021;None. Available from: None.
20.
Notohamiprodjo S, Nekolla SG, Robu S, Villagran Asiares A, Kupatt C, Ibrahim T, et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04. J. Nucl. Cardiol. [Internet]. 2021;None. Available from: None.
21.
Siebermair J, Köhler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J. Nucl. Cardiol. [Internet]. 2021;28:812–21. Available from: None.
22.
Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2022;49:2786–97. Available from: None.
23.
Diekmann J, Koenig T, Thackeray JT, Derlin T, Czerner C, Neuser J, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with magnetic resonance tissue characterization and subsequent functional outcome. J. Nucl. Med. [Internet]. 2022;None:jnumed.121.263555. Available from: None.
24.
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2020;47:1820–32. Available from: None.
25.
Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:4377–85. Available from: None.
26.
Çermik TF, Ergül N, Yılmaz B, Mercanoğlu G. Tumor imaging with 68Ga-DOTA-FAPI-04 PET/CT: comparison with 18F-FDG PET/CT in 22 different cancer types. Clin. Nucl. Med. [Internet]. 2022;47:e333–9. Available from: None.
27.
Lan L, Liu H, Wang Y, Deng J, Peng D, Feng Y, et al. The potential utility of [68Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:963–79. Available from: None.
28.
Fu W, Liu L, Liu H, Zhou Z, Chen Y. Increased FAPI uptake in brain metastasis from lung cancer on 68Ga-FAPI PET/CT. Clin. Nucl. Med. [Internet]. 2021;46:E1–2. Available from: None.
29.
Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2019;46:2569–80. Available from: None.
30.
Qin C, Liu F, Huang J, Ruan W, Liu Q, Gai Y, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:3228–37. Available from: None.
31.
Gu B, Xu X, Zhang J, Ou X, Xia Z, Guan Q, et al. The Added Value of 68Ga-FAPI-PET/CT in patients with head and neck cancer of unknown primary with 18F-FDG negative findings. J. Nucl. Med. [Internet]. 2022;63. Available from: None.
32.
Chen S, Chen Z, Zou G, Zheng S, Zheng K, Zhang J, et al. Accurate preoperative staging with [68Ga]Ga-FAPI PET/CT for patients with oral squamous cell carcinoma: a comparison to 2-[18F]FDG PET/CT. Eur. Radiol. [Internet]. 2022;None. Available from: None.
33.
Zhao L, Pang Y, Zheng H, Han C, Gu J, Sun L, et al. Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:3606–17. Available from: None.
34.
Zhao L, Pang Y, Lin Q, Chen H. Cardiac angiosarcoma detected using 68Ga-fibroblast activation protein inhibitor positron emission tomography/magnetic resonance. Eur. Heart J. [Internet]. 2021;42:1276. Available from: None
35.
Xu T, Ding H, Ban H, Zhu Y, Chen Y. 68Ga-DOTA-FAPI-04 PET/CT imaging in a case of cardiac angiosarcoma. Clin. Nucl. Med. [Internet]. 2022;Publish Ah. Available from: None.
36.
Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Uzun E, et al. Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Ann. Nucl. Med. [Internet]. 2021;35:1321–31. Available from: None.
37.
Kömek H, Can C, Güzel Y, Oruç Z, Gündoğan C, Yildirim ÖA, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann. Nucl. Med. [Internet]. 2021;35:744–52. Available from: None.
38.
Peng D, He J, Liu H, Cao J, Wang Y, Chen Y. FAPI PET/CT research progress in digestive system tumours. Dig. Liver Dis. [Internet]. 2022;54:164–9. Available from: None.
39.
Fu L, Huang S, Wu H, Dong Y, Xie F, Wu R, et al. Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur. Radiol. [Internet]. 2022;None. Available from: None.
40.
Gündoǧan C, Kömek H, Can C, Yildirim ÖA, Kaplan İ, Erdur E, et al. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma. Nucl. Med. Commun. [Internet]. 2022;43:64–72. Available from: None.
41.
Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:732–42. Available from: None.
42.
Kömek H, Can C, Kaplan İ, Gündoğan C, Kepenek F, Karaoglan H, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer. Eur J Nucl Med Mol Imaging [Internet]. 2022;142:109867. Available from: None.
43.
Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2022;49:743–50. Available from: None.
44.
Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2022;49:2960–71. Available from: None.
45.
Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology [Internet]. 2021;298:393–402. Available from: None.
46.
Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET/CT. J. Nucl. Med. [Internet]. 2022;63:81–8. Available from: None.
47.
Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:1604–17. Available from: None.
48.
Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:1593–603. Available from: None.
49.
Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:196–203. Available from: None.
50.
Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul P, Boonkawin N, Chinnanthachai C, et al. Comparisons of quantitative parameters of Ga-68-labelled fibroblast activating protein inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in patients with liver malignancies. Mol. Imaging Biol. [Internet]. 2022;None. Available from: None.
51.
Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma. Front. Oncol. [Internet]. 2021;11. Available from: None.
52.
Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2022;49:1322–37. Available from: None.
53.
Rohrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of 68ga-fapi pet/ct imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J. Nucl. Med. [Internet]. 2021;62:779–86. Available from: None.
54.
Novruzov E, Dendl K, Ndlovu H, Choyke PL, Dabir M, Beu M, et al. Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer. Mol. Imaging Biol. [Internet]. 2022;None. Available from: None.
55.
Pang Y, Wei J, Shang Q, Zhao L, Chen H. 68Ga-fibroblast activation protein inhibitor, a promising radiopharmaceutical in PET/CT to detect the primary and metastatic lesions of chromophobe renal cell carcinoma. Clin. Nucl. Med. [Internet]. 2021;46:177–9. Available from: None.
56.
Dendl K, Koerber SA, Finck R, Mokoala KMG, Staudinger F, Schillings L, et al. 68Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:4089–100. Available from: None.
57.
Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:73–86. Available from: None.
58.
Chen Y, Zheng S, Zhang J, Yao S, Miao W. 68Ga-DOTA-FAPI-04 PET/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients. Ann. Nucl. Med. [Internet]. 2022;36:610–22. Available from: None.
59.
Alan-Selçuk N, Ergen S, Demirci E, Ocak M, Kabasakal L. [68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:4523–4. Available from: None.
60.
Fan C, Guo W, Su G, Chen B, Chen H. Widespread metastatic gastric signet-ring cell carcinoma shown by 68Ga-FAPI PET/CT. Clin. Nucl. Med. [Internet]. 2021;46:e78–9. Available from: None.
61.
Şahin E, Elboğa U, Çelen YZ, Sever ÖN, Çayırlı YB, Çimen U. Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur. J. Radiol. [Internet]. 2021;142. Available from: None.
62.
Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:1944–55. Available from: None.
63.
Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Okuyan M, et al. Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT modalities in gastrointestinal system malignancies with peritoneal involvement. Mol. Imaging Biol. [Internet]. 2022;None. Available from: None.
64.
Wu J, Wang Y, Liao T, Rao Z, Gong W, Ou L, et al. Comparison of the relative diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the detection of bone metastasis in patients with different cancers. Front. Oncol. [Internet]. 2021;11. Available from: None.
65.
Huang Y, Cao J, Peng D, Liu H, Chen Y. Bone marrow metastases from gastric adenocarcinoma on 68Ga-FAPI-04 PET/CT. Clin. Nucl. Med. [Internet]. 2022;47:151–3. Available from: None.
66.
Li Y, Lin X, Li Y, Lv J, Hou P, Liu S, et al. Clinical utility of F-18 labeled fibroblast activation protein inhibitor (FAPI) for primary staging in lung adenocarcinoma: a Prospective Study. Mol. Imaging Biol. [Internet]. 2022;24:309–20. Available from: None.
67.
Wang L, Tang G, Hu K, Liu X, Zhou W, Li H, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of advanced lung cancer. Radiology [Internet]. 2022;303:191–9. Available from: None.
68.
Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A, et al. Higher accuracy of [68Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:2983–93. Available from: None.
69.
Kessler L, Ferdinandus J, Hirmas N, Bauer S, Dirksen U, Zarrad F, et al. 68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial. J. Nucl. Med. [Internet]. 2022;63:89–95. Available from: None.
70.
Gu B, Liu X, Wang S, Xu X, Liu X, Hu S, et al. Head-to-head evaluation of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging [Internet]. 2022;49:2889–901. Available from: None.
71.
Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results. J. Nucl. Med. [Internet]. 2022;63:415–23. Available from: None.
72.
Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J. Nucl. Med. [Internet]. 2022;63:727–34. Available from: None.
73.
Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J. Nucl. Med. [Internet]. 2017;58:445–50. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27660138.
74.
Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur. J. Nucl. Med. Mol. Imaging [Internet]. 2021;48:3011–3. Available from: None.
75.
Fu H, Huang J, Sun L, Wu H, Chen H. FAP-targeted radionuclide therapy of advanced radioiodine-refractory differentiated thyroid cancer with multiple cycles of 177Lu-FAPI-46. Clin. Nucl. Med. [Internet]. 2022;Publish Ah. Available from: None.
76.
Sharma P, Singh SS, Gayana S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging tool. Clin. Nucl. Med. [Internet]. 2021;46:e141–50. Available from: None.
77.
Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, Rösch F, Rominger A, et al. New frontiers in cancer imaging and therapy based on radiolabeled fibroblast activation protein inhibitors: A rational review and current progress. Pharmaceuticals [Internet]. 2021;14. Available from: None.
78.
Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front. Oncol. [Internet]. 2021;11. Available from: None.
79.
Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-head comparison of fibroblast activation protein inhibitors (Fapi) radiotracers versus [18f]f-fdg in oncology: a systematic review. Int. J. Mol. Sci. [Internet]. 2021;22. Available from: None.
80.
Roustaei H, Kiamanesh Z, Askari E, Sadeghi R, Aryana K, Treglia G. Could fibroblast activation protein (FAP)-specific radioligands be considered as Pan-tumor agents? Contrast Media Mol. Imaging [Internet]. 2022;2022. Available from: None.
81.
Gilardi L, Farulla LSA, Demirci E, Clerici I, Salè EO, Ceci F. Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET. Biomedicines [Internet]. 2022;10. Available from: None.
Metadata
Title
Current research topics in FAPI theranostics: a bibliometric analysis
Authors
Andor F. van den Hoven
Ruth G. M. Keijsers
Marnix G. E. H. Lam
Andor W. J. M. Glaudemans
Frederik A. Verburg
Wouter V. Vogel
Jules Lavalaye
Publication date
28-11-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-06052-9

Other articles of this Issue 4/2023

European Journal of Nuclear Medicine and Molecular Imaging 4/2023 Go to the issue

Guidelines

EANM practice guideline for quantitative SPECT-CT

Original Article

Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

Review Article

Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications

Original Article

Decentralized collaborative multi-institutional PET attenuation and scatter correction using federated deep learning

Original Article

Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study

Original Article

The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies